Oculis-2026-JPM.pdf

1、Visionary InnovationRiad Sherif,M.D.Chief Executive OfficerJ.P.Morgan Healthcare ConferenceJanuary 14,2026These slides and the accompanying oral presentation contain forward-looking statements and information.The use of words such as“may,”“might,”“will,”“should,”“expect,”“plan,”“anticipate,”“believe

2、,”“estimate,”“project,”“intend,”“future,”“potential,”or“continue,”and other similar expressions are intended to identify forward-looking statements.For example,all statements we make regarding the initiation,timing,progress and results of our preclinical studies,our clinical studies,ourresearch and

3、development programs,our regulatory strategy,our future development plans,our ability to advance product candidates into,and successfully completeclinical studies,and the timing or likelihood of regulatory filings and approvals,our cash runway,and statements regarding the potential therapeutic benef

4、its of ourproduct candidates are forward looking.All forward-looking statements are based on estimates and assumptions by our management that,although we believe to bereasonable,are inherently uncertain.All forward-looking statements are subject to risks and uncertainties that may cause actual resul

5、ts to differ materially from thosethat we expected.Factors that may cause actual results to differ materially from current expectations include,but are not limited to:the possibility that Oculis may beadversely affected by economic,business,and/or competitive factors;Oculis estimates of expenses and

6、 profitability;Oculis ability to develop,manufacture andcommercialize the product candidates in its pipeline;actions of regulatory authorities,which may affect the initiation,timing and progress of clinical studies or futureregulatory approvals or marketing authorizations;the ability of Oculis or it